FILTER
FILTERED INTERVIEW RESULTS
Francisco Portilla
GENERAL MANAGER, PLASMA 4TH
Plasma 4th provides has developed cleaner, quieter and less invasive blasting solutions using plasma.
Jarl Kåreson Hakvåg
CHARTERING SOUTH AMERICA AC/USG, ODFJELL TANKERS
Odfjell is the second largest specialized tanker company for chemical transportation in the world.
Timothy Beale
PRESIDENT & CEO, REVELO RESOURCES
Chile-based Revelo Resources wants to take its prospect generation business model to the next level.
Stephanie Ashton
CFO AND CORPORATE DEVELOPMENT, GRIFFITH DRILLING
Griffith Drilling provides specialized drilling services to the mining industry in Chile
Edmundo Puentes
GENERAL MANAGER, OXIQUIM
"In the recent years, Oxiquim’s terminal and logistics business has grown significantly. Approximately 70% of LPG imported into Chile is handled at Oxiquim’s terminals, and we are currently in the process of building a new LPG terminal in Mejillones.”
Guillermo Laborato
PRESIDENT, LATIN AMERICA SOUTH, BRENNTAG
Despite a challenging economic environment, Brenntag’s Latin American operations continue to experience growth.
Jorge Buckup
PRESIDENT LATIN AMERICA, UNIVAR SOLUTIONS
Univar Solutions is expanding its business in the Latin America region through a series of acquisitions.
João Parolin
CEO, OXITENO
Chemical manufacturing company Oxiteno is exploting opportunities in the United States while maintaining an eye on economic recovery in Latin America.
Julio Garcia
OWNER AND GENERAL MANAGER, ADIZOL
ADIZOL is the distributor for the global specialty chemicals company Lubrizol in Chile, where the lubricant and fuel markets remain key.
Ramón Opazo
CEO, ANTIRION
Antirion provides risk management services through a web-based software platform.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
